WILMINGTON, Del.--(BUSINESS WIRE)-- VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with ...
Dr Haumschild continues leading an expert discussion surrounding key strategies and pain points in PNH treatment. Please describe the significance of the different efficacy end points explored for ...
A meta-analysis on complement inhibitors in the management of paroxysmal nocturnal hemoglobinuria (PNH) reveals an association between these interventions and positive treatment outcomes. Complement ...
SÃO PAULO--(BUSINESS WIRE)--Pint Pharma and OrphanDC announced on July 25th that ANVISA, the National Health Surveillance Agency, approved, on July 25th, 2023, the drug EMPAVELI® (pegcetacoplan, ...
Basel, June 11, 2021 — Novartis today announced new Phase II data for iptacopan (LNP023), an investigational oral treatment for paroxysmal nocturnal hemoglobinuria (PNH), presented at the 26th Annual ...
"We need longer follow-up with the newer complement inhibitors to be sure that they’re safe long-term and that there won’t be excessive intravascular breakthrough hemolysis/thrombosis. Some of these ...
National Institute for Health and Care Excellence (NICE) has recommended iptacopan (Fabhalta, Novartis) as a new treatment option for adults with paroxysmal nocturnal haemoglobinuria (PNH) and ...
LOUISVILLE, Ky.--(BUSINESS WIRE)--Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Novartis for Fabhalta ® (iptacopan) as the first oral ...
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare immune disease that causes your body to break down red blood cells when it should not. This disorder happens when there is a problem with certain ...
In this interview, we spoke with Gloria Gerber, MD, a hematologist and assistant professor of medicine at Johns Hopkins University, about the evolution of treatment for paroxysmal nocturnal ...
With AstraZeneca’s dominance in the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) threatened by the recent approval of the first pill on the market for the condition, Novartis’ Fabhalta ...
Ilene Weitz, MD, discusses research on several new therapies for paroxysmal nocturnal hemoglobinuria (PNH) with promising clinical impact presented at ASH 2024. The APPLY-PNH and APPOINT-PNH studies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results